We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
Read MoreHide Full Article
Key Takeaways
Amgen wins FDA approval for Uplizna in generalized myasthenia gravis for adults with key antibody profiles.
The drug offers twice-yearly dosing and showed strong efficacy in the phase III MINT study.
The approval expands Amgen's rare disease portfolio as Uplizna enters a competitive gMG market.
Amgen (AMGN - Free Report) announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in adults who have tested positive for anti-AChR or anti-MuSK antibodies.
With this approval, Uplizna is now the first CD19-targeted B-cell therapy approved for this patient population. Although many drugs are approved in the gMG space, the Amgen drug offers patients a twice-yearly dosing option — a significant advantage over existing therapies that require more frequent administrations.
The FDA’s decision is supported by data from the phase III MINT study, which showed strong efficacy benefits in gMG patients following treatment with Uplizna. gMG is an autoantibody-driven neuromuscular disease marked by fluctuating muscle weakness.
This marks the second approval for Uplizna this year and its third overall in the United States. In April, the drug became the first FDA-approved treatment for adults with a rare autoimmune disease called immunoglobulin G4-related disease (IgG4-RD). Uplizna is also approved for neuromyelitis optica spectrum disorder (NMOSD), another rare autoimmune disease.
The drug is part of Amgen’s rare disease franchise and was added to its portfolio following the acquisition of Horizon Therapeutics for nearly $28 billion in 2023. The approval strengthens Amgen’s presence in high-value autoimmune markets and expands the commercial potential of its rare disease portfolio.
Competition in the gMG Space
Post approval, Uplizna enters a highly competitive market for gMG therapies. Despite offering the key advantage of twice-yearly dosing, Amgen’s drug will compete directly with argenx’s (ARGX - Free Report) Vyvgart/Vyvgart Hytrulo, J&J's (JNJ - Free Report) Imaavy and Belgium-based UCB’s Rystiggo for market share.
While Vyvgart/Vyvgart Hytrulo is approved only for patients with anti-AChR positive antibodies, both Imaavy and Rystiggo — like Uplizna — are approved for patients who test positive for either anti-AChR or anti-MuSK antibodies. Notably, all three competing therapies from argenx, J&J and UCB share a common mechanism: they block the neonatal Fc receptor (FcRn) to treat gMG.
Another important distinction is age eligibility. While Amgen’s Uplizna, argenx’s Vyvgart/Vyvgart Hytrulo and UCB’s Rystiggo are approved only for adult patients, J&J’s Imaavy is approved for both adults and adolescents aged 12 years and older, potentially giving it a broader prescriber base.
AMGN’s Price Performance, Valuation and Estimates
Shares of Amgen have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.67 times forward earnings compared to the industry's average of 16.59. The stock is trading above its five-year mean of 13.73.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have risen in the past 30 days.
Image: Bigstock
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
Key Takeaways
Amgen (AMGN - Free Report) announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug is approved to treat the disease in adults who have tested positive for anti-AChR or anti-MuSK antibodies.
With this approval, Uplizna is now the first CD19-targeted B-cell therapy approved for this patient population. Although many drugs are approved in the gMG space, the Amgen drug offers patients a twice-yearly dosing option — a significant advantage over existing therapies that require more frequent administrations.
The FDA’s decision is supported by data from the phase III MINT study, which showed strong efficacy benefits in gMG patients following treatment with Uplizna. gMG is an autoantibody-driven neuromuscular disease marked by fluctuating muscle weakness.
This marks the second approval for Uplizna this year and its third overall in the United States. In April, the drug became the first FDA-approved treatment for adults with a rare autoimmune disease called immunoglobulin G4-related disease (IgG4-RD). Uplizna is also approved for neuromyelitis optica spectrum disorder (NMOSD), another rare autoimmune disease.
The drug is part of Amgen’s rare disease franchise and was added to its portfolio following the acquisition of Horizon Therapeutics for nearly $28 billion in 2023. The approval strengthens Amgen’s presence in high-value autoimmune markets and expands the commercial potential of its rare disease portfolio.
Competition in the gMG Space
Post approval, Uplizna enters a highly competitive market for gMG therapies. Despite offering the key advantage of twice-yearly dosing, Amgen’s drug will compete directly with argenx’s (ARGX - Free Report) Vyvgart/Vyvgart Hytrulo, J&J's (JNJ - Free Report) Imaavy and Belgium-based UCB’s Rystiggo for market share.
While Vyvgart/Vyvgart Hytrulo is approved only for patients with anti-AChR positive antibodies, both Imaavy and Rystiggo — like Uplizna — are approved for patients who test positive for either anti-AChR or anti-MuSK antibodies. Notably, all three competing therapies from argenx, J&J and UCB share a common mechanism: they block the neonatal Fc receptor (FcRn) to treat gMG.
Another important distinction is age eligibility. While Amgen’s Uplizna, argenx’s Vyvgart/Vyvgart Hytrulo and UCB’s Rystiggo are approved only for adult patients, J&J’s Imaavy is approved for both adults and adolescents aged 12 years and older, potentially giving it a broader prescriber base.
AMGN’s Price Performance, Valuation and Estimates
Shares of Amgen have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, Amgen is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 14.67 times forward earnings compared to the industry's average of 16.59. The stock is trading above its five-year mean of 13.73.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have risen in the past 30 days.
Image Source: Zacks Investment Research
Amgen currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.